



Introduction: The reorganisation of the structure of a Gastro-Intestinal Oncology 
Multidisciplinary Team Meeting (GIO-MDTM) in a tertiary centre with three care 
pathways is evaluated on added value.
Methods: In a mixed method investigation, process indicators such as throughput 
times were analysed and stakeholders were interviewed regarding benefits and 
drawbacks of the reorganisation and current MDTM functioning.
Results: For the hepatobiliary care pathway, the time to treatment plan increased, but 
the time to start treatment reduced significantly. The percentage of patients treated 
within the Dutch standard of 63 days increased for the three care pathways. From 
the interviews, three themes emerged: added value of MDTMs, focus on planning 
integrated care and awareness of possible improvements.
Discussion: The importance of evaluating interventions in oncology care pathways is 
shown, including detecting unexpected drawbacks. The evaluation provides insight 
into complex dynamics of the care pathways and contributes with recommendations 
on functioning of an MDTM.
Conclusions: Throughput times are only partly determined by oncology care pathway 
management, but have influence on the functioning of MDTMs. Process indicator 
information can help to reflect on integration of care in the region, resulting in an 
increase of patients treated within the Dutch standard.
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INTRODUCTION
Care pathways are accepted as a means to manage 
oncology care [1]. The management team of an 
oncological care pathway, tumour board, generally 
consists of a group of specialists that focus on 1) 
communication between different specialists on 
managing evidence-based treatment for oncology 
patients, 2) decision making in multidisciplinary team 
meetings (MDTMs) for oncology patients who need 
complex treatment plans and 3) multidisciplinary 
coordination of integrated care with timely start of 
treatment within the region [2, 3, 4]. MDTMs use digital 
medical records and clinical decision support systems in 
different ways [5, 6]. MDTMs make a valuable contribution 
to the choice and planning of treatment [7, 8, 9] and lead 
to a better survival rate [10, 11, 12, 13]. Consequently, 
MDTMs are considered the gold standard in oncology care 
pathway management [14, 15, 16, 17, 18, 19, 20, 21] 
and the platform to accomplish clinical integration [22]. 
For optimal coordination and clear communication 
with patients, uniformity in working methods with 
standardised formats for MDTMs are advocated by 
European [23, 24], Canadian [25] and American cancer 
treatment associations [26]. Additionally, MDTMs are also 
used for coordinating research, education, promoting 
and for diffusing best practices and new developments, 
so called ‘functional integration’ [22].
The Gastro-Intestinal Oncology (GIO) tumour board of 
our University Medical Centre (UMC) is a tertiary centre 
that organises oncology care together with partners 
in the northern region of the Netherlands and shares 
responsibility for optimising quality and improving the 
integration of care. This GIO tumour board manages 
care pathways for three groups of malignancies: 
colorectal, hepatobiliary and esophagus-stomach. In 
the Netherlands, the number of gastrointestinal cancer 
cases rose from 12,877 in 1989 to 23,985 in 2018, an 
increase of 86%. Especially the increase in fragile, elderly 
patients with gastrointestinal cancer led to a need for 
more complex care. This complexity led to lengthier 
discussions, longer MDTMs and longer throughput times 
for the patient to get a treatment plan. Given these 
trends, the UMC-GIO tumour board decided to reorganise 
the care pathways according to a previous developed 
model [27]. The aim of that reorganization was to make 
the care pathways more patient-centred, enabling 
shared decision making and to reduce throughput times 
to comply with the standards set by the Dutch Healthcare 
Inspectorate, formulated in the SONCOS standards 
(Stichting Oncologische Samenwerking: Council for 
Oncological Collaboration) [28]. The main interventions 
were: 1) immediate triage with direct ordering of missing 
diagnostics upon receival of the referral, 2) assessment 
of the patient before the MDTM in the outpatient clinic 
on the same day as the MDTM, 3) presence of the right 
specialisms during each MDTM to formulate an optimal 
multidisciplinary treatment plan and 4) seeing the 
patient shortly after the MDTM, on the same day, to share 
the proposal for treatment and decide together with the 
patient (shared decision making).
The care pathways start with referral to the UMC by a 
general practitioner or a specialist (tertiary or quaternary; 
Supplement 1). Before the reorganisation, patients 
following the colorectal and esophagus-stomach care 
pathways were seen at the oncology outpatient clinic 
before their treatment plan was discussed in an MDTM 
[29]. In several cases the diagnostic work-up was not 
yet complete. In the hepatobiliary care pathway usually 
images with a treatment plan were discussed at the MDTM 
before patients were invited to the oncology outpatient 
clinic. Due to the quaternary function, consultation ‘on 
paper’ is requested regularly and not all patients require 
to visit the UMC (e.g. a non-resectable tumour eligible 
for palliative chemotherapy can be handled by their 
local physician). As of April 2015, the triage with direct 
ordering of missing diagnostics was implemented. The 
first assessment of the patient in the outpatient clinic, 
GIO-intake, was on the same day as the MDTM in which 
their treatment plan was formulated (Figure 1). Decisions 
in the MDTMs are made by dedicated specialists involved in 
diagnostics and treatment for that GIO pathway. Directly 
after the MDTM, on the same day, the treatment options 
and consequences are explained to the patient. Specialisms 
involved in the treatment have the opportunity to speak 
with the patient. The reorganization did not change the 
role of the case managers, they plan the activities for 
diagnostic procedures and treatment in the same way.
When throughput times started to increase again, 
the GIO tumour board felt the need to evaluate the 
reorganisation by comparing its throughput times and the 
number of MDTMs per patient. In this study, we evaluated 
quantitatively the throughput times, number of hospital 
visits and number of MDTMs [11, 30], and qualitatively 
the benefits and drawbacks of the reorganisation by 
interviewing specialists and case managers. This mixed 
methods approach sought to answer two questions:
1. What is the added value of the GIO-MDTM 
reorganisation in terms of throughput times, number 
of MDTMs and number of hospital visits?
2. What benefits and drawbacks do stakeholders of 
each care pathway perceive from the reorganisation 
of the GIO-MDTM and how could functioning of 




In a previous study on the effects of reorganising a care 
pathway for patients with head-and-neck cancers, data 
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retrieved from 25 medical records before and 25 after a 
reorganisational intervention were sufficient to show a 
significant reduction in throughput times and hospital 
visits [31].
We therefore choose to analyse, for each care 
pathway, two sets of medical records, 25 before and 25 
after the reorganisation. The first set included data on 25 
consecutive patients referred at least four months before 
the start of the GIO-MDTM reorganisation, working back 
from December 31st 2014. The other set included data 
who were referred four months after the reorganisation, 
i.e. from August 1st 2015 onwards. Data were included 
on patients who were at least 18 years old and who had 
been discussed in a GIO-MDTM in our UMC. The following 
tumours were selected (ICD-O-03 ed1/ed3 [32]): 
esophagus C15, stomach C16, colon C18, rectum C209, 
pancreas C250, liver C220 and gall bladder C239. Data on 
patients treated for benign or neuroendocrine tumours 
were not included.
Process evaluation and study design
For process evaluation of the reorganization of GIO-
MDTM, throughput times, the number of MDTMs per 
patient and the number of hospital visits were used as 
process indicators (i.e. quantitative outcome variables 
for this study). Throughput times were measured as the 
times from triage to the moment the treatment plan was 
available and to start treatment (Figure 1).
National standards
In assessing the added value, or efficiency, of the 
reorganisation we used modified SONCOS standards. 
The tertiary centre’s responsibility starts the moment 
the referral request is received and the centre obviously 
has no direct influence on the part of the care pathway 
before this referral. The standards state that, for patients 
with a GIO tumour, the throughput time for diagnostic 
procedures should be no more than 21 days; and that 
the throughput time from oncology intake, if referred 
to a tertiary treatment facility, to the start of primary 
treatment no more than 63 days. As the starting point 
for these throughput times, the standards take the day 
that the results of the biopsy, taken in the referring 
hospital, are known. Instead, we took timing of triage in 
our institution as starting day for throughput times. Thus, 
in this study, we set targets of 21 days for the time to 
Figure 1 Before and after the reorganization with indicators.
Legend: The green and purple arrows indicate TTP and TST respectively. For an explanation see the methods section Process 
indicators and study design.
Abbreviations: GIO: Gastro-Intestinal Oncology, MDTM: Multidisciplinary team meeting; TTP: Time to Treatment Plan and TST: Time to 
Start Treatment, TT: Throughput Time, UMC: University Medical Centre.
In the schematic arrows: *: Colorectal (CR), **: Esophagus-Stomach (ES), ***: Hepatobiliary (HPB) tertiary, ****: Hepatobiliary quaternary.
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get the treatment plan and 63 days for the time to start 
treatment (Figure 1).
Sometimes, tumour size was missing in the treatment 
plan. In these instances, we used Netherlands Cancer 
Registry data to retrieve missing tumour size data and to 
confirm dates we extracted from medical records.
Statistical analysis
To analyse whether the GIO-MDTM reorganisation 
had different effects for the different care pathways, a 
univariate general linear model analysis was performed. 
However, the assumptions for this type of analysis were 
not satisfied. Subsequently, several attempts were 
made to transform the data to meet the assumptions, 
but these failed because our data were too skewed. 
Instead we analysed effects of the reorganisation within 
each care pathway non-parametrically and report 
medians and interquartile ranges (IQR). Differences in 
age, gender, tumour localisation (ICD-O), tumour size, 
diagnostic type, treatment type and compliance with the 
21-days standard and the 63-days standard, before and 
after the reorganisation of the GIO-MDTM, were analysed 
using Chi-Squared tests or Chi-Squared test exact if 
requirements were not met. Mann-Whitney-U tests were 
used to analyse throughput time differences. Statistical 
analyses were performed using SPSS 23.0 for Windows 
software. Statistical significance was set at 5%.
QUALITATIVE COMPONENT
Semi-structured interviews were held with gate-keeping 
specialists and case managers from the three care 
pathways. The interviews focussed on perceived benefits 
and drawbacks, and the value of the reorganisation, the 
current functioning of the GIO-MDTM and how MDTMs 
could be further improved.
Interviews
During October and November 2019, three surgeons, 
three gastroenterologists and three case managers 
were interviewed. After receiving their verbal informed 
consent, semi-structured interviews started with 
providing information on the quantitative results of this 
study. The interview continued with the question: ‘What 
do you think is the role of the gate-keeping specialist / 
case manager in a GIO-MDTM?’. The interviewer used a 
topic list as interview guide (Supplement 2). Interviews 
lasted 25 to 40 minutes, were audio recorded and 
transcribed.
Thematic analysis
Quotes were extracted from the transcripts. The 
participants were asked to review and confirm their 
personal transcripts and extracted quotes. Quotes were 
then anonymised. In the first stage of the inductive 
analysis [31, 32], codes were given to quotes related 
to the reorganisation of the GIO-MDTM and its current 
functioning [30, 33, 34, 35]. The codes were placed in a 
coding tree in relation to the research question with three 
main themes: planning for integrated care, added value 
of the MDTM and the management of the care pathway 
(Supplement 3) [36, 37]. Thereafter a second coder gave 
quotes codes from the coding tree. Codes were judged 
as either being a benefit or a drawback that could be 
improved. Disagreements in coding between the coders 
and the researcher were discussed. After the preliminary 




In total, data from 194 medical records were included 
in this study; 96 before and 98 after the reorganisation 
(Supplement 4: Tables a-c). All groups had at least 25 
patients that started treatment. A data check revealed 
that 3% of the data were not in accordance with 
the Netherlands Cancer Registry and were changed 
accordingly. The throughput times based on the 
Netherlands Cancer Registry database were shorter than 
those based on medical records (mean difference 0.5 
days). Staging verification showed no differences for the 
tumour sizes. Mean (sd) age of patients before and after 
the reorganisation was 66.2 (9.3) respectively 65.4 (12.5) 
years. In all the pathways, tumours were somewhat 
larger after the reorganisation. Outliers were explored 
and, in most cases, comorbidity induced extended 
throughput times.
In the colorectal care pathway, after the 
reorganisation, the number of hospital visits in the period 
from triage to start of treatment tended to increase (p = 
.092) (Table 1 and Figure 3a). Nevertheless, the standards 
for throughput times from triage to get the treatment 
plan and from triage to start treatment were met for a 
higher proportion of patients after the reorganisation (85 
vs 93%).
In the hepatobiliary care pathway, more primary 
tumours were treated after the reorganisation (p = .039) 
(Supplement 4: Table b), the time to get the treatment 
plan increased (p =.035) but the time to start treatment 
decreased (p = .029) (Table 1 and Figure 2a). The number 
of hospital visits between triage and treatment plan 
increased (p = .027), and more MDTMs were needed 
to come to a treatment plan (p = .026) after the 
reorganisation. After the reorganisation fewer patients 
got their treatment plan within 21 days. The percentage 
of patients that started their treatment within 63 days 
increased to 88% (p = .024).
In the esophagus-stomach care pathway, patients in 
our post-reorganisation sample were older than those in 
the pre-reorganisation sample (p = .050) and the number 
of hospital visits needed to come to a treatment plan was 
less after the reorganisation (p = .037). The number of 
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MDTMs per patient tended to decrease (p = .079; Table 1). 
The percentage of patients that started their treatment 
within 63 days increased and in 2015 the standard of 63 
days was met for all.
QUALITATIVE ANALYSIS
From the transcripts, 251 quotes were extracted. 
In total 50 codes (Supplement 3) were identified 
related to the reorganisation of the GIO-MDTM and its 
current functioning. These codes were given 630 times 
(Supplement 3). Inter-coder agreement was 62.5%. 
Codes representing a benefit (30 codes identified, 418 
times) were given twice as often than those representing 
a drawback (20 codes, 212 times). The 10 most frequently 
given codes were given to 56 % of the 251 quotes.
During a thematic synthesis, three main themes emerged 
from the data; 1) increase of the added value of the 
MDTMs, for example availability of expert specialisms 
had increased, 2) greater focus in the planning on 
continuity and integration of care, for example planning in 
cooperation with other regional hospitals had improved, 3) 
greater awareness that improvements could be made in 
the management of GIO care pathways, such as using a 
dashboard to monitor ‘real time’ relevant throughput times 
for GIO patients on the hospital’s MDTM registration list.
The added value of the GIO-MDTMs (codes 17–34)
Most interviewees regarded a GIO-MDTM as the moment 
where all expertise comes together to decide an optimal 
multidisciplinary treatment plan. A gastroenterologist 
explained:
“The value of the MDTM is twofold: 1) for the 
patient who visits the GIO outpatient clinic, you 
Figure 2 (a) Box and whisker plots time to treatment plan. (b) Box and whisker plots time to start treatment.
Legend: CR: colorectal, HPB: hepatobiliary, ES: esophagus-stomach; TST: time to start treatment; TTP: time to treatment plan.
Blue is before and green is after the MDTM reorganisation; O: outlier, *: outlier Tukey’s method IQR; IQR: Inter Quartile Range.
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have thought carefully about the possible diagnosis 
and multidisciplinary treatment (code 24) 2) it is 
good for the cohesion within the team, to know 
your colleagues with whom you work well, which 
means that you can also find each other easily in 
other circumstances.” (code 18).
During a GIO-MDTM, the gate-keeping specialism for 
each patient is responsible for the quality of the intake 
and presents their patients. That specialism thus plays a 
key role for patients and also for colleagues. In addition, 
the chair of the GIO-MDTM also fills an important role. 
The chair has to monitor and guide the meeting process, 
summarise discussions and formulate the conclusions. 
The chair needs to distinguish non-complex cases, or 
‘formalities’, from complex cases to ensure an efficient 
discussion. A surgeon said:
“As chair, I prepare for a meeting thoroughly. I 
review the patients to estimate the time needed 
for each one: a ‘formality’ or an extended 
discussion.” (code 26).
Each care pathway had different dynamics reflecting 
differences in the biology of the tumours. Although 
participants noted that it is important to prepare for the 
MDTM, most specialisms did not schedule time for this. A 
surgeon said:
Figure 3 (a) Box and whisker plots number of hospital visits from triage to treatment plan. (b) Box and whisker plots number of 
hospital visits between triage and start treatment.
Legend: hospitals visits per patient (CR: colorectal, HPB: hepatobiliary, ES: esophagus-stomach).
Blue is before and green is after the MDTM reorganisation; O: outlier.
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“It is both time consuming and important for a 
chair to prepare well for the MDTM, but no time 
is scheduled for this the day before our MDTM.” 
(code 23).
The participants stated that good preparation makes the 
MDTM more efficient for all persons present and it is good 
for patient care. A case manager said:
“Everybody wants time to reflect on their own 
preparation for the MDTM, because it is their 
patient being presented who needs an optimal 
treatment plan.” (code 32).
Focus in planning on continuity and integrated 
care (codes 1–16)
The case managers played a distinct role in the care 
pathway. They focused on all patients’ needs, including 
psychosocial aspects. They aim to speed up the diagnostic 
process by getting information from the referrer where 
possible and, during that process, they stay in contact 
with the patient, the referring hospital and the treating 
specialist, signalling problems in throughput times and 
acting to prevent delays when possible. A case manager 
said:
“The role of the case manager is to prepare the 
agenda for the MDTM and to act upon decisions of 
the MDTM.” (code 8).
A surgeon member of a tumour board put it like this:
“We steer tightly, using the case manager to 
acquire diagnostic results from the periphery on 
time. A few times, the results had not arrived on 
time, but we decided to discuss the patient at the 
MDTM with the information at hand.” (code 11).
The latter part of this quote reflects a dilemma we heard 
several times: helping the patient is more important than 
a perfect process in the hospital. Another aspect of the 
case manager’s focus on the patient and on integrated 
care was that they implemented an improvement shortly 
after the reorganisation of the GIO-MDTM. Patients had 
commented that they understood the diagnosis and the 
treatment plan, but that the explanation of the different 
treatment options and consequences was too much for 
them to digest in a single hospital visit.
GIO care pathways management and 
improvement awareness (codes 35–50)
Most interviewees stated that further improvements 
could be made, but that finding time to reflect and 
gain support to implement improvements was difficult. 
Throughput times cannot always be influenced by a 
physician or care pathway management. The available 
time in the operating theatre is in part determined by 
the capacity of the anaesthesiology department. A 
gastroenterologist said:
“The throughput time of 6–8 weeks for an 
Endoscopic Retrograde Cholangiopancreatography 
is determined by the sedation capacity of [the 
department of] anaesthesiology.”. A dashboard 
with indicators was seen as potentially helpful. A 
surgeon member of a tumour board said:
“We should have a dashboard to monitor our 
registration list for the GIO-MDTM in relation to 
relevant throughput times.” (code 46).
Another aspect highlighted was that not all parties 
involved in the GIO-MDTM were invited to meetings where 
policy and improvement opportunities were discussed. A 
case manager said:
“A tumour board manages our care pathway. As a 
case manager or nursing consultant, you are not 
invited to the policy meetings.” (code 45).
DISCUSSION
QUANTITATIVE RESULTS
After the reorganisation, throughput times to start 
treatment decreased significantly but throughput times 
to get the treatment plan increased in the hepatobiliary 
pathway. In the two other pathways, the percentages of 
cases meeting the 21-day standard set for the treatment 
plan increased somewhat but not significantly. In all the 
pathways, a higher percentage of cases met the standard 
to start treatment within 63 days, but only significantly 
in the hepatobiliary pathway. The number of MDTMs 
increased significantly in the hepatobiliary pathway. 
The number of hospital visits from triage to treatment 
plan increased significantly in the hepatobiliary pathway 
but decreased significantly in the oesophagus-stomach 
pathway.
The reorganisation aimed to reduce throughput 
times by standardising the work for the majority of 
non-complex patients and thereby gaining time to 
discuss the more complex cases. In the UMC, as a 
tertiary and quaternary centre, an increasing number 
of older patients with more comorbidities are seen, 
which explains an increase in larger tumours. Generally 
complex patients with advanced diseases benefit most 
from MDTM discussions, also described as the ‘Flying 
Dutchman phenomenon’ blown from one site-specific 
MDTM to another until finally reaching safe haven 
[29]: patients getting the best possible treatment plan 
through a multidisciplinary approach in a tertiary centre 
[12, 29, 39, 40]. Developments required more intensive 
discussion and coordination between professionals 
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and this is reflected in increased throughput times and 
number of hospital visits from triage to treatment plan 
in the hepatobiliary pathway. During the reorganization 
there were no task shifts from doctors to nurses or to 
general practitioners. An explanation for the decrease 
in throughput time from triage to start treatment in the 
hepatobiliary pathway (a 9-day difference in median 
times), despite a longer throughput time from triage to 
treatment plan, could be improved case coordination 
as a result of the reorganisation of the MDTM. Given the 
increasing percentage of complex cases, we argue that the 
SONCOS standards are too strict in expecting throughput 
times to be met for all patients. Indeed, for head-and-
neck cancer patients in the Netherlands [41, 42], there 
has been a modification, now expecting 80% of patients 
to meet the time to start treatment. Therefore, we would 
recommend healthcare policymakers to set throughput 
time standards but expect hospitals to only meet these 
for about 75% [43, 44].
In the hepatobiliary pathway, before the reorganisation, 
patients were not seen in the outpatient clinic before 
the MDTM and decisions were taken based on imaging 
and documents. After the reorganisation, patients were 
seen before the MDTM, and additional hospital visits were 
scheduled to prepare for the treatment. This change 
resulted in longer throughput times and an increase in 
the number of MDTMs. Recently a re-evaluation project 
was started with the region to optimize the care pathway 
including the development of a dashboard.
In the colorectal care pathway, the number of hospital 
visits also tended to increase after the reorganisation. 
Intake and assessment by different specialties on the 
same day as the GIO-intake resulted in an overwhelming 
amount of information being presented to the patient. 
It was therefore decided to arrange an additional visit 
to explain the medical situation and the alternative 
treatments to the patient and their supporters. For 
such patients, efficiency has its limits: they need time 
for explanation and reflection in order to make a ‘well-
weighted, shared decision’ with their treating specialist 
e.g. in an elderly MDTM [45].
Conversely, for the esophagus-stomach care pathway, 
the number of MDTMs tended to decrease as well as the 
number of hospital visits needed to come to a treatment 
plan. Another improvement was seen in the integration of 
surgical capacity. Here, since January 2019, a secondary 
hospital in the region shares its surgical capacity with 
the UMC’s GIO centre for stomach surgery. The MDTMs 
held by UMC and by the secondary hospital have been 
merged and using video-conferencing to reduce the 
number of MDTMs and decrease throughput times. 
Research on care pathway management in Scotland 
has shown that throughput time measurements on 
several levels should be taken into account to improve 
coordination in a region [46], and this is reflected in our 
recommendations below.
QUALITATIVE RESULTS
Twice as many codes were annotated as benefits than as 
drawbacks for the functioning of the GIO-MDTM. However, 
some of the benefits were already experienced as an 
advantage of having MDTMs before the reorganisation. 
From the interviews, it became clear that, following the 
reorganisation, the value of the MDTMs had increased. 
The different treatment modalities were better discussed 
between the appropriate specialisms with more attention 
to patient wishes. This was largely caused by availability 
of all expertise at the meeting to discuss complex cases 
and to cooperate in a multidisciplinary way in formulating 
an optimal treatment plan for individual patients. In 
this way, the reorganisation enhanced quality and 
integration of care for the three patient groups and, 
what is more, the interviewees said that the reorganised 
MDTMs also improved interpersonal relations between 
participants. These improvement contributed positively 
to discussions and resulted in better treatment plans. 
These findings are in line with previous study findings 
[47, 48]. Another observation was the improvement in 
case coordination due to the more complete presence 
of required disciplines during the MDTM and the better 
relationships. Although the importance of improved case 
coordination between healthcare professionals with 
better interpersonal relationships has also been found 
previously [49, 50, 51, 52], more research is needed to 
understand the underlying processes and the way it adds 
value to a care pathway.
Case managers believed that throughput times to 
get the treatment plan and throughput times to start 
treatment could be further reduced through stricter 
monitoring of the completeness of the diagnostic 
information needed to start treatment. The importance 
of strict monitoring has been identified elsewhere [53, 54] 
but we noticed that the ‘circle of influence’ of a care 
coordinator or case manager is limited. The case manager 
has no control over or mandate for discipline-bounded 
capacities such as slots for diagnostic procedures. Such 
a mandate depends on the leadership and style of 
communication in the tumour board and the MDTM.
From the interviews, it became clear that the GIO-
MDTMs would benefit from participants being better 
prepared. Specialists within the same department could 
discuss treatment possibilities from their perspective 
before the MDTM, and prepare questions to discuss with 
other specialists to optimise the proposed treatment. In 
general, there is no preparation time scheduled for the 
MDTM participants. The chair should be well prepared, 
and should earmark time for the different disciplines, 
so that discussions within a discipline during an MDTM 
would then take less time and the MDTM would be more 
efficient. Surgical oncologists elsewhere have reported 
that MDTM members have good insight into their own 
multidisciplinary team performance and state that 
all MDTMs would benefit from good leadership, good 
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preparation of MDTMs and appropriate presentation 
of information by the gate-keeping specialists 
[55, 56, 57, 58].
All participants of the GIO-MDTMs were highly 
motivated to improve efficiency of the meetings 
but they experienced a lack of time to prepare the 
meetings. Although the UMC, as a tertiary centre, treats 
mainly the more complex cases, there are sufficient 
surgical treatments to meet the SONCOS indicator for 
the ‘number of surgical cases’, which is an indicator 
for being a ‘competent’ surgeon [28]. However, this 
indicator should not be seen as justification for adversely 
affecting the time available for participants to prepare 
for an MDTM. Additionally, there remains a dilemma for 
the hepatobiliary pathway. The efficiency of the care 
pathway in terms of diagnostic procedures against the 
importance of meeting the patient before making a 
treatment plan at the MDTM so that the patient’s wishes 
concerning treatment can get more attention and can be 
optimally included [59].
COMBINING QUANTITATIVE AND QUALITATIVE 
RESULTS
The interviews provided an insight into the complex 
dynamics of oncology care pathways and the functioning 
of their MDTMs. Collaboration in an MDTM is not only 
about efficiency and indicators like throughput times, but 
also about cooperation, respect for other team members 
and the commitment of all team members, and good 
leadership [12, 48, 60].
The importance of evaluating interventions in oncology 
care pathways is shown, including detecting unexpected 
drawbacks. This study showed the importance of 
evaluating adjustments or interventions in internal and 
regional care pathways in order to detect any unexpected 
drawbacks, to structure continuous improvement [43, 61] 
and to organize care pathways in an integrated way. This 
mixed method approach, provides insight into how an 
oncology care pathway operates, the contribution of the 
individual members, their appreciation and assessment 
of the cooperation [62].
LIMITATIONS OF THIS STUDY
A limitation of this study is the lack of generally accepted 
indicators for care pathway management and definitions 
of those indicators that do exist [46, 57, 63]. We modified 
Dutch SONCOS standardised indicators to evaluate 
the reorganisation of the care pathways in order to be 
comparable to the indicators used in earlier research on 
the care pathway of head-and-neck cancer patients [31]. 
Contrary to our expectations, we did not find a significant 
decrease in throughput times for the different GIO care 
pathways. We saw that the clinical presentation, the 
biological behaviour of tumours, types of treatment and 
treatment combinations differed considerably from the 
care pathway of head-and-neck cancers. Further, we 
noted that the UMC’s focus increasingly on the care of 
complex patients with larger tumours, that the incidence 
of tumours in the elderly is increasing, and that these 
factors may be important confounders in not finding a 
significant change following reorganisation.
RECOMMENDATIONS
Based on the results of our study, we formulated the 
following recommendations
1. Make a policy plan with the region, for a specific 
period with accurate, recent performance data and 
reflect on possibilities to improve the care pathway 
(code 17).
2. Create a team of people who know and trust each 
other, who promote interaction and commitment 
using a U-form table in their meeting rooms (code 
44) where colleagues can confront each other 
respectfully about desirable and undesirable 
behaviours (code 18).
3. Ensure all specialist disciplines attend the 
MDTM (code 24 and code 25) to formulate the 
best treatment plan for each patient, including 
customisation for complex or comorbid cases 
(code 10).
4. Make medical and psychosocial information available 
during MDTMs (code 31) and include patient wishes 
in the treatment plan e.g. by planning an elderly 
MDTM before the treatment MDTM (code 14).
5. Provide clarity on everybody’s individual role, before, 
during (code 22) and after the meeting to optimise 
time management during the MDTM (code 30).
6. The chair should show leadership and motivate 
the team by taking responsibility for directing the 
discussion in the meetings and summarise the 
conclusions and formulate the treatment plans 
according to the format in the guidelines (code 26).
7. Provide all MDTM participants with dedicated time 
to prepare for the meeting (code 23) since this will 
increase meeting efficiency and the quality of the 
treatment plan (code 22).
8. Set up an integrated dashboard to monitor relevant 
real time indicators for your care pathway, such as 
‘throughput time differences from standard’ or hospital 
visits, and evaluate the performance (code 46).
The results and recommendations show that improving 
performance requires an improved functioning of MDTMs 
(clinical integration), participation of all specialists 
with clear roles (professional integration), resources 
such as time, sufficient performance information and 
quality improvement efforts (functional integration), 
a regional policy (organizational integration) and 
shared commitment and mutual trust to improve the 
performance of the pathway (normative integration) 
[22].
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However ‘real time’-dashboard implementation is 
complicated for functional integration in a care pathway, 
but is currently under development.
FURTHER RESEARCH
To justify the existence of time-consuming events such 
as MDTMs in oncological care pathways, it is important 
to measure their added value. Further research could be 
directed at investigating the value of real time dashboard 
information, and consider the waiting times and the 
status of diagnostic procedures in reaching a personalised 
treatment plan in an MDTM. On the tumour board level, 
further research could focus on what indicators enable 
effective care pathway management. For example, 
indicators that 1) present real time throughput time 
information on diagnostic procedures and treatment steps, 
2) enable informed decision-making on diagnostic and 
therapeutic capacity and 3) increase efficiency by reducing 
non-value adding diagnostic procedures or treatments.
CONCLUSIONS
Reorganising the GIO-MDTM and outpatient clinic had 
different effects on each care pathway. For the hepatobiliary 
pathway, the throughput time from triage to treatment 
plan increased, but the throughput time from triage to 
start treatment reduced. No other significant changes 
were identified. Overall, the percentage of patients treated 
within the Dutch standard of 63 days increased.
The efficacy of an integrated multidisciplinary care 
pathway needs constant attention. It can be assessed with 
a mixed method approach. Beside results of quantitative 
evaluation like throughput times, a qualitative approach 
is recommended for assessment of the human factor in 
cooperation between different disciplines.
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